ESMO Congress

Ribociclib combined with aromatase inhibitors significantly enhances invasive disease-free survival in early breast cancer, offering lasting benefits beyond treatment.

Abemaciclib plus endocrine therapy significantly improves overall survival in high-risk early breast cancer, reducing death risk by 15.8% compared to endocrine therapy alone.

Alectinib shows promising long-term survival benefits over crizotinib in advanced ALK-positive lung cancer, highlighting significant clinical advancements.

Lenvatinib combined with pembrolizumab and chemotherapy shows no significant survival benefit over pembrolizumab plus chemotherapy in metastatic esophageal cancer.

Durvalumab enhances disease-free survival in high-risk non-muscle invasive bladder cancer when combined with BCG therapy, according to recent trial results.

Sevabertinib shows promising efficacy in treating HER2-mutant advanced NSCLC, achieving high response rates and durable outcomes in clinical trials.

Anbenitamab plus chemotherapy significantly improves survival rates in HER2-positive gastric cancer patients, offering a promising new treatment option.

Durvalumab combined with FLOT chemotherapy significantly enhances overall survival in resectable gastric adenocarcinoma, establishing a new standard of care.

Zongertinib shows promising results as a first-line treatment for advanced HER2-mutant NSCLC, achieving high response rates and significant clinical benefits.

Dr. Joyce O'Shaughnessy discusses the monarchE trial's findings, emphasizing the importance of abemaciclib in reducing breast cancer recurrence and improving patient access.

New findings from the monarchE trial reveal long-term benefits of abemaciclib in reducing recurrence risk for high-risk early breast cancer patients.

Discover the most anticipated abstracts on gastrointestinal cancers at the 2025 ESMO Congress, featuring groundbreaking studies and innovative treatments.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.

Discover the most anticipated late-breaking abstracts in gastrointestinal cancers at ESMO 2025 and influence the conversation in oncology research.

A groundbreaking trial reveals trastuzumab deruxtecan significantly improves survival in high-risk HER2-positive breast cancer patients post-neoadjuvant therapy.

Nicolas Girard, MD, PhD, discusses patient-reported outcomes from the LUMINOSITY trial of telisotuzumab vedotin in NSCLC.

John Strickler, MD, discusses targeting c-Met as a biomarker in gastric and gastroesophageal junction cancers.

Meredith McKean, MD, MPH, discussed findings from a longer-term follow-up study evaluating fianlimab plus cemiplimab for the treatment of metastatic melanoma.

Nicolas Girard, MD, PhD, discusses the rationale of targeting PD-L1 and LAG-3 in NSCLC in the RELATIVITY-104 study.

Angeles Alvarez Secord, MD, MHSc, discusses key takeaways from the PICCOLO trial.

Toni Choueiri, MD, discusses the rationale behind the drug combination of tivozanib and nivolumab in the TiNivo-2 study.

Nancy Lin, MD, discusses the efficacy of T-DXd for brain metastases as seen in DESTINYBreast-12 compared with other agents.

Sun Gwe Ahn, MD, discusses an exploratory analysis of the HERA trial at the 2024 ESMO Congress.

Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented at the 2024 ESMO Congress.

NKT2152, a novel oral HIF-2α inhibitor, showed promising results in treating advanced clear cell renal cell carcinoma, with an objective response rate of 20% in all-comers and 26.3% in the dose-escalation population.

The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical activity in patients with ER-positive, HER2-negative metastatic breast cancer who had previously received endocrine therapy and another CDK4/6 inhibitor.

CheckMate-9ER post hoc analysis suggests certain sugar molecules on blood proteins may predict how well niovlumab and cabozantinib in kidney cancer treatment works.

The GigaPath AI model was highlighted for its advanced capabilities in predicting cancer mutations and tumor mutation burden, including those in lung cancer and other malignancies.

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading experts.